Cargando…

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

IMPORTANCE: Based on contemporary estimates in the US, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To determine the use of evidence-based cardiovascular preventiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelson, Adam J., O’Brien, Emily C., Kaltenbach, Lisa A., Green, Jennifer B., Lopes, Renato D., Morse, Caryn G., Al-Khalidi, Hussein R., Aroda, Vanita R., Cavender, Matthew A., Gaynor, Tanya, Kirk, Julienne K., Lingvay, Ildiko, Magwire, Melissa L., McGuire, Darren K., Pak, Jonathan, Pop-Busui, Rodica, Richardson, Caroline R., Senyucel, Cagri, Kelsey, Michelle D., Pagidipati, Neha J., Granger, Christopher B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855234/ https://www.ncbi.nlm.nih.gov/pubmed/35175345 http://dx.doi.org/10.1001/jamanetworkopen.2021.48030

Ejemplares similares

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study
por: Aroda, Vanita R., et al.
Publicado: (2021)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Cardiac Autonomic Neuropathy in Diabetes: A clinical perspective
por: Pop-Busui, Rodica
Publicado: (2010)

Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
por: Lingvay, Ildiko, et al.
Publicado: (2023)

Acitretin Treatment for Lipoid Proteinosis
por: Gündüz, Özgür, et al.
Publicado: (2012)

Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?
por: Das, Arup, et al.
Publicado: (2016)

Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11)
por: Amod, Aslam, et al.
Publicado: (2019)

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)
por: Amod, Aslam, et al.
Publicado: (2020)

Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
por: Martin, Catherine L., et al.
Publicado: (2014)

Hypoglycemia unawareness and autonomic dysfunction in diabetes: Lessons learned and roles of diabetes technologies
por: Lin, Yu Kuei, et al.
Publicado: (2020)

Metformin and Type 2 Diabetes Prevention
por: Aroda, Vanita R., et al.
Publicado: (2018)

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale
por: Yassin, Sayf A, et al.
Publicado: (2017)

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment
por: Aroda, Vanita R., et al.
Publicado: (2022)

Response to Comment on Mizokami-Stout et al. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. Diabetes Care 2020;43:806–812
por: Mizokami-Stout, Kara R., et al.
Publicado: (2020)

Response to Comment on Jaiswal et al. Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study. Diabetes Care 2017;40:1226–1232
por: Jaiswal, Mamta, et al.
Publicado: (2018)

Update on the Management of Diabetic Neuropathy
por: Ang, Lynn, et al.
Publicado: (2018)

Empirical Antibiotic Therapy in Diabetic Foot Ulcer Infection Increases Hospitalization
por: Schmidt, Brian M, et al.
Publicado: (2023)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022)

Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?
por: Aroda, Vanita R., et al.
Publicado: (2018)

Evidence-Based Pharmacotherapy for Pediatric Obsessive-Compulsive Disorder and Chronic Tic Disorders
por: De Nadai, Alessandro S., et al.
Publicado: (2011)

Prevalence and Determinants of Glycemic Abnormalities in Cardiac Surgery Patients without a History of Diabetes: A Prospective Study
por: Gianchandani, Roma Y., et al.
Publicado: (2015)

HARP Versus SinMod for measuring regional heart function from tagged CMR images
por: Ibrahim, El-Sayed H, et al.
Publicado: (2016)

CMR for evaluation of cardiac function in Type-1 diabetes
por: Ibrahim, El-Sayed H, et al.
Publicado: (2016)

Identification of Factors Associated With Sural Nerve Regeneration and Degeneration in Diabetic Neuropathy
por: Hur, Junguk, et al.
Publicado: (2013)

Impaired Amino Acid and TCA Metabolism and Cardiovascular Autonomic Neuropathy Progression in Type 1 Diabetes
por: Mathew, Anna V., et al.
Publicado: (2019)

Accessibility and Openness to Diabetes Management Support With Mobile Phones: Survey Study of People With Type 1 Diabetes Using Advanced Diabetes Technologies
por: Lin, Yu Kuei, et al.
Publicado: (2022)

The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia
por: Cotter, Jack, et al.
Publicado: (2019)

Pharmacotherapy of Insomnia
por: Neubauer, David N, et al.
Publicado: (2018)

Altered sphingoid base profiles in type 1 compared to type 2 diabetes
por: Wei, Nancy, et al.
Publicado: (2014)

Strategies to reduce severe diabetic foot infections and complications during epidemics (STRIDE)()
por: Schmidt, Brian M., et al.
Publicado: (2020)

COVID-19 and Diabetes: A Collision and Collusion of Two Diseases
por: Feldman, Eva L., et al.
Publicado: (2020)

Pharmacotherapy of smoking cessation
por: Jiloha, R. C.
Publicado: (2014)

Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences
por: Horowitz, Michael, et al.
Publicado: (2017)

Urinary epidermal growth factor levels correlate with cardiovascular autonomic neuropathy indices in adults with type 1 diabetes
por: Lin, Yu Kuei, et al.
Publicado: (2023)

Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
por: Zisman, Ariel, et al.
Publicado: (2018)

Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-L
por: Blonde, Lawrence, et al.
Publicado: (2020)

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures
por: Lingvay, Ildiko, et al.
Publicado: (2017)

Triglycerides and Amputation Risk in Patients With Diabetes: Ten-year follow-up in the DISTANCE study
por: Callaghan, Brian C., et al.
Publicado: (2011)

Burden of Diabetic Peripheral Neuropathy in Pima Indians With Type 2 Diabetes
por: Jaiswal, Mamta, et al.
Publicado: (2016)

Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
por: Truong, Van Thi Thanh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fa95m7vmb6a255l8hk148a3cvj